

Experts for medical co-operations.

hcp+



PLASMAJET

PLASMAJET V3+

HARNESSING PURE-PLASMA ENERGY FOR SURGERY

- Established surgical system to leverage the unique properties of thermal plasma
- Over 40,000 surgeries conducted in more than 20 countries
- Proven results and a distinctive value supported by a large clinical database



PLASMAJET ULTRA+
GROUNDBREAKING
PURE-PLASMA ENERGY
FOR SURGERY¹

- Combines plasma with ultrasonic energy to create enhanced functionality and versatility
- Unique fine dissection using kinetic energy
- Vaporization with blended coagulation
- Advanced coagulation modes for routine hemostasis
- Range of surface sealing functions for different tissues types
- Intuitive operation with improved usability
- Large spectrum of surgical procedures



ALL SURGICAL ACTIONS
USING PURE-PLASMA²

- No electrical current to the patient
- Minimal thermal spread
- No arcing with metal instruments
- Control to work around sensitive structures

PRODUCT COMPARISON

PLASMAJET V3+

PLASMAJET ULTRA+



COAGULATION

Limited

Surface coagulation

Routine coagulation

Small vessel management

Optimized presets

SEALING

Limited

Surface sealing

Improved control

Tissue specific modes

Optimized presets

DISSECTION

Kinetic

Kinetic

Fine & ultrafine

Blended with sealing

Optimized presets

VAPORIZATION

Microlayer

Microlayer

Blended with sealing

Optimized presets

CONTACT US

HCP Healthcarepartner GmbH

Wolfgangsee Straße 26, 5023 Salzburg-Guggenthal, Österreich

T +43 (0)662/621243 • F -11 • office@hcp-austria.com

hcp-austria.com

¹ Indications for Use: "The PlasmaJet Ultra+ is a neutral plasma surgery system that is designed for surgical dissection by cutting, coagulation and the removal of soft tissue by vaporization in open surgery and laparoscopic surgery"; PlasmaJet Ultra+ Operator Manual; Compared to PlasmaJet V3+.

² Madhuri et al – Pathologic Analysis of Tissue Destruction, 2012; [2010 Sonoda Ovarian Ca and Peritoneal Ca]; Noppenhuis et al – PlasmaJet Ablation and Resection of Carcinomatosis in Ovarian Cancer, 2013; Renaud et al – Optimal Cyto-reduction in Selected Patients with Ovarian and Primitive Peritoneal Cancer, 2013; Plasma Technology and its Clinical Application - Whitepaper Plasma Surgical 2013, 1-7; Product Technical File; Product Usability Study; [2013 Roman Endometrioma].